JP2022549335A5 - - Google Patents

Info

Publication number
JP2022549335A5
JP2022549335A5 JP2022519061A JP2022519061A JP2022549335A5 JP 2022549335 A5 JP2022549335 A5 JP 2022549335A5 JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022549335 A5 JP2022549335 A5 JP 2022549335A5
Authority
JP
Japan
Prior art keywords
psychosis
symptoms
schizophrenia
disorder
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022519061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052923 external-priority patent/WO2021062307A1/en
Publication of JP2022549335A publication Critical patent/JP2022549335A/ja
Publication of JP2022549335A5 publication Critical patent/JP2022549335A5/ja
Priority to JP2025182550A priority Critical patent/JP7821366B1/ja
Withdrawn legal-status Critical Current

Links

JP2022519061A 2019-09-25 2020-09-25 新規方法 Withdrawn JP2022549335A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182550A JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906042P 2019-09-25 2019-09-25
US62/906,042 2019-09-25
PCT/US2020/052923 WO2021062307A1 (en) 2019-09-25 2020-09-25 Novel methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182550A Division JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Publications (2)

Publication Number Publication Date
JP2022549335A JP2022549335A (ja) 2022-11-24
JP2022549335A5 true JP2022549335A5 (https=) 2023-10-02

Family

ID=75166462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519061A Withdrawn JP2022549335A (ja) 2019-09-25 2020-09-25 新規方法
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Country Status (4)

Country Link
US (2) US12478623B2 (https=)
EP (1) EP4034119A4 (https=)
JP (2) JP2022549335A (https=)
WO (1) WO2021062307A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373288B1 (ko) * 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
EP4273550A3 (en) 2018-05-17 2024-04-03 Northeastern University Lipid-free anchoring of thermophilic bacteriophage g20c portal adapter into solid-state nanopores
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2021007245A1 (en) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
IL300886A (en) * 2020-09-04 2023-04-01 Intra Cellular Therapies Inc New salts, crystals and co-crystals
WO2025111568A1 (en) * 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
SK7042003A3 (en) 2000-12-20 2004-07-07 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20050058703A1 (en) 2003-08-01 2005-03-17 Chang Robert C. Gelatin capsules
JP4912320B2 (ja) 2004-12-07 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換された四環式テトラヒドロピラン、ピロリジンおよびテトラヒドロチオフェン誘導体
AU2006275702A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
NZ586963A (en) 2008-02-05 2012-11-30 Clera Inc Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition
AU2009223701B2 (en) 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
EP3085231A1 (en) 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AR092568A1 (es) 2012-09-14 2015-04-22 Abbvie Deutschland Derivados triciclicos de quinolinas y de quinoxalinas
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2017120012A1 (en) 2016-01-05 2017-07-13 The Regents Of The University Of California Methods of treating mental disorders
PL3838274T3 (pl) * 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
PL3497104T3 (pl) 2016-08-09 2022-02-21 Teva Pharmaceuticals International Gmbh Postacie w stanie stałym soli ditosylanowej lumateperonu
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
WO2019023062A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
EP3658144B1 (en) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
CN109867674A (zh) 2017-12-05 2019-06-11 上海度德医药科技有限公司 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
US20210008065A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
AU2019280850C1 (en) 2018-06-06 2025-02-13 Intra-Cellular Therapies, Inc. Novel salts and crystals
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
BR112021003655A2 (pt) * 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
EP3887374A2 (en) 2018-11-27 2021-10-06 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
WO2021007245A1 (en) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
WO2021127572A1 (en) 2019-12-19 2021-06-24 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
CN119486738A (zh) 2022-05-18 2025-02-18 细胞内治疗公司 新方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Similar Documents

Publication Publication Date Title
JP2022549335A5 (https=)
AU2021202433B2 (en) Neuroactive steroids, compositions, and uses thereof
KR102228598B1 (ko) 최면 진정제의 투여 방법
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
JP2017509686A5 (https=)
JP2003503450A5 (https=)
DE4218572A1 (de) Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
JP2008545793A5 (https=)
CN109843889A (zh) 螺-内酰胺nmda调节剂和使用其的方法
US9782404B2 (en) Methods of treating disease-induced ataxia and non-ataxic imbalance
JP2021505575A5 (https=)
JP7429942B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
US10647679B2 (en) N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
EA021962B1 (ru) Способ лечения шизофрении
JP2019516756A5 (https=)
ES2963362T3 (es) Métodos de uso de derivados de amidas cíclicas para tratar la esquizofrenia y sus síntomas
RU2019132951A (ru) Применение обратного агониста h3r для лечения расстройства сна при сменной работе
Varghese et al. Lamotrigine‐induced toxic epidermal necrolysis in three patients treated for bipolar disorder
TWI494106B (zh) Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途
JP2011520964A (ja) ニコチン性アセチルコリン受容体活性を有する化合物を用いる末梢感覚神経喪失の治療方法
JP2025505261A5 (https=)
JP2010509389A (ja) 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ［１，２−ａ］イミダゾールジオン
JP7740804B2 (ja) 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
JPH02212426A (ja) 医薬組成物
BR112020011586A2 (pt) 3(2-(4-(2-metoxifenil)piperazin-1-il)etil)quinazolin-4(3h)-ona, sais farmaceuticamente aceitáveis, tratamento do transtorno do estresse pós-traumático, composição farmacêutica, formas de dosagem e uso